PT  - JOURNAL ARTICLE
AU  - Paolo Bossi
AU  - Cristina Gurizzan
AU  - Luigi Lorini
AU  - Pierluigi di Mauro
AU  - Chiara Sardini
AU  - Marco Merlano
TI  - Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
AID  - 10.1136/jitc-2021-003154
DP  - 2021 Aug 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e003154
VI  - 9
IP  - 8
4099  - http://jitc.bmj.com/content/9/8/e003154.short
4100  - http://jitc.bmj.com/content/9/8/e003154.full
SO  - J Immunother Cancer2021 Aug 01; 9
AB  - Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies to elucidate their potential positive or negative consequences on the outcomes when administered with immunotherapeutic agents.